FEMASYS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.3 USD | +2.36% |
|
+0.79% | +31.28% |
| 04-01 | HC Wainwright Adjusts Femasys' Price Target to $12 From $10, Reiterates Buy Rating | MT |
| 03-28 | Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 5.02M 399M | Sales 2025 * | 16.69M 1.33B | Capitalization | 28.07M 2.23B |
|---|---|---|---|---|---|
| Net income 2024 * | -15M -1.19B | Net income 2025 * | -15M -1.19B | EV / Sales 2024 * | 5.6 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.68 x |
| P/E ratio 2024 * |
-1.84
x | P/E ratio 2025 * |
-3.63
x | Employees | 33 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.87% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.36% | ||
| 1 week | +0.79% | ||
| Current month | -17.42% | ||
| 1 month | -25.58% | ||
| 3 months | +60.02% | ||
| 6 months | -7.91% | ||
| Current year | +31.28% |
1 week
1.21
1.41
1 month
1.211.84
Current year
0.732.40
1 year
0.254.75
3 years
0.2513.75
5 years
0.2513.75
10 years
0.2513.75
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 56 | 31/12/03 | |
Dov Elefant
DFI | Director of Finance/CFO | 56 | 27/02/22 |
James Liu
CTO | Chief Tech/Sci/R&D Officer | - | 11-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charlie Larsen
CHM | Chairman | 72 | 13/10/15 |
Joshua Silverman
BRD | Director/Board Member | 53 | 11-20 |
| Founder | 56 | 31/12/03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 1.28 | +0.79% | 57 895 |
| 26/04/24 | 1.27 | -4.51% | 138,216 |
| 25/04/24 | 1.33 | 0.00% | 103,654 |
| 24/04/24 | 1.33 | 0.00% | 114,142 |
| 23/04/24 | 1.33 | +4.72% | 282,476 |
Delayed Quote Nasdaq, April 29, 2024 at 07:06 pm
More quotes
Femasys Inc. is a biomedical company. The Company is focused on addressing unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The Company also developed a technology platform, namely FemEMB for tissue sampling intended to be marketed alongside its other women-specific medical products in the physicianâs office setting.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.27
USD
Average target price
9.75
USD
Spread / Average Target
+667.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.28% | 28.07M | |
| -2.79% | 187B | |
| -1.97% | 106B | |
| -4.48% | 66.9B | |
| +0.65% | 49.45B | |
| +16.56% | 48B | |
| +4.06% | 40.84B | |
| +3.61% | 26.48B | |
| +0.91% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- FEMY Stock
